Amphastar Pharmaceuticals to Present at the 37th Annual Piper Sandler Healthcare Conference

Rhea-AI Summary

Amphastar Pharmaceuticals (NASDAQ:AMPH) said Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will take part in an analyst-moderated fireside chat at the 37th Annual Piper Sandler Healthcare Conference on Wednesday, December 3, 2025 at 2:00 PM ET.

The presentation will be available via webcast on Amphastar's investor website and will remain accessible for 30 days after the event.

RANCHO CUCAMONGA, CA / ACCESS Newswire / November 24, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will be participating in an Analyst-Moderated fireside chat at the 37^th Annual Piper Sandler Healthcare Conference on Wednesday, December 3^rd, 2025, at 2:00 pm ET. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.

About Amphastar Pharmaceuticals, Inc.:

Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin active pharmaceutical ingredient products. Most of the Company's finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information is available at the Company's website at www.amphastar.com.

The Amphastar Pharmaceuticals' logo, and other trademarks or service marks of Amphastar Pharmaceuticals, Inc., including, but not limited to BAQSIMI^®, Primatene MIST^®, REXTOVY^®, Amphadase^®, and Cortrosyn^®, are the property of Amphastar Pharmaceuticals, Inc.

Forward Looking Statements

All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth, sales and marketing of our products, market size and expansion, product portfolio, product development, the timing of FDA filings or approvals, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the impact of our products, including their potential for continued revenue growth, the strategic trajectory of and market for our product pipeline, our ability to leverage our existing expertise and technology, the impacts of any licensing agreements and ability to commercialize additional therapies, our manufacturing in-house expertise, our commercial momentum and position in the market. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission ("SEC"), including in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 3, 2025, in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 8, 2025, in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed with the SEC on August 7, 2025, in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, filed with the SEC on November 6, 2025, and our other filings or reports that we may file with the SEC. In particular, there can be no guarantee that our sales strategies will be successful, or that we will continue to experience significant sales of BAQSIMI^®. You can locate these reports through our website at http://ir.amphastar.com and on the SEC's website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change.

Contact:

Bill Peters Chief Financial Officer (909) 476-3416

SOURCE: Amphastar Pharmaceuticals, Inc.

View the original press release on ACCESS Newswire

FAQ

When will Amphastar (AMPH) present at the Piper Sandler Healthcare Conference?

Amphastar will present on December 3, 2025 at 2:00 PM ET.

Who from Amphastar will speak during the AMPH presentation on December 3, 2025?

Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will participate in the fireside chat.

How can investors access Amphastar's (AMPH) webcast at the Piper Sandler conference?

Access the live webcast via Amphastar's investor site at http://ir.amphastar.com.

How long will Amphastar's (AMPH) Piper Sandler webcast be available after the presentation?

The webcast will be available for 30 days following the presentation.

What topics will Amphastar (AMPH) executives likely address at the December 3, 2025 fireside chat?

The company indicated executives will discuss regulatory and clinical operations and answer analyst questions during the moderated fireside chat.